FDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer

Season 4 Episode 38  ·  Mar 08, 2021, 07:37 PM
Headliner
Share
Subscribe

In our exclusive interview, Dr. Shitara discussed the significance of the FDA approval of trastuzumab deruxtecan in HER2-positive gastric and GEJ adenocarcinoma and key efficacy and safety data that have been reported with the agent.

Share
Subscribe
Next
Levy Lauds Biomarker-Driven Data in Lung Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air